Literature DB >> 29257865

Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.

Christopher M Hartshorn1, Michelle S Bradbury2, Gregory M Lanza3, Andre E Nel4, Jianghong Rao5, Andrew Z Wang6, Ulrich B Wiesner7, Lily Yang8, Piotr Grodzinski1.   

Abstract

Ongoing research into the application of nanotechnology for cancer treatment and diagnosis has demonstrated its advantages within contemporary oncology as well as its intrinsic limitations. The National Cancer Institute publishes the Cancer Nanotechnology Plan every 5 years since 2005. The most recent iteration helped codify the ongoing basic and translational efforts of the field and displayed its breadth with several evolving areas. From merely a technological perspective, this field has seen tremendous growth and success. However, an incomplete understanding of human cancer biology persists relative to the application of nanoscale materials within contemporary oncology. As such, this review presents several evolving areas in cancer nanotechnology in order to identify key clinical and biological challenges that need to be addressed to improve patient outcomes. From this clinical perspective, a sampling of the nano-enabled solutions attempting to overcome barriers faced by traditional therapeutics and diagnostics in the clinical setting are discussed. Finally, a strategic outlook of the future is discussed to highlight the need for next-generation cancer nanotechnology tools designed to address critical gaps in clinical cancer care.

Entities:  

Keywords:  Cancer Nanotechnology Plan; National Cancer Institute; alliance; biological barriers; cancer; image-guided surgery; immunotherapy; metastasis; nanotechnology; oncology; radiotherapy

Mesh:

Year:  2017        PMID: 29257865      PMCID: PMC6589353          DOI: 10.1021/acsnano.7b05108

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  167 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 2.  Incidence, location, and diagnostic evaluation of metastatic bone disease.

Authors:  W D Hage; A J Aboulafia; D M Aboulafia
Journal:  Orthop Clin North Am       Date:  2000-10       Impact factor: 2.472

Review 3.  Bone marrow cells in the 'pre-metastatic niche': within bone and beyond.

Authors:  Rosandra N Kaplan; Bethan Psaila; David Lyden
Journal:  Cancer Metastasis Rev       Date:  2006-12       Impact factor: 9.264

4.  A pooled analysis of bone marrow micrometastasis in breast cancer.

Authors:  Stephan Braun; Florian D Vogl; Bjørn Naume; Wolfgang Janni; Michael P Osborne; R Charles Coombes; Günter Schlimok; Ingo J Diel; Bernd Gerber; Gerhard Gebauer; Jean-Yves Pierga; Christian Marth; Daniel Oruzio; Gro Wiedswang; Erich-Franz Solomayer; Günther Kundt; Barbara Strobl; Tanja Fehm; George Y C Wong; Judith Bliss; Anne Vincent-Salomon; Klaus Pantel
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

5.  Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.

Authors:  Anne Gangloff; Wei-Ann Hsueh; Amanda L Kesner; Dale O Kiesewetter; Betty S Pio; Mark D Pegram; Malgorzata Beryt; Allison Townsend; Johannes Czernin; Michael E Phelps; Daniel H S Silverman
Journal:  J Nucl Med       Date:  2005-11       Impact factor: 10.057

Review 6.  Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors.

Authors:  J A Dowell; A R Sancho; D Anand; W Wolf
Journal:  Adv Drug Deliv Rev       Date:  2000-03-15       Impact factor: 15.470

Review 7.  Clinical use of intensity-modulated radiotherapy: part I.

Authors:  M T Guerrero Urbano; C M Nutting
Journal:  Br J Radiol       Date:  2004-02       Impact factor: 3.039

8.  Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.

Authors:  Zhen Cheng; Jianqing Chen; Yubin Miao; Nellie K Owen; Thomas P Quinn; Silvia S Jurisson
Journal:  J Med Chem       Date:  2002-07-04       Impact factor: 7.446

9.  Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells.

Authors:  Takashi Maeda; Caroline M Alexander; Andreas Friedl
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

10.  Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer.

Authors:  Tanja Fehm; Sven Becker; Graziella Becker-Pergola; Karl Sotlar; Gerhard Gebauer; Silke Dürr-Störzer; Hans Neubauer; Diethelm Wallwiener; Erich-Franz Solomayer
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

View more
  40 in total

Review 1.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

2.  Size-Optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-Based Differential Targeting in Triple Negative Breast Cancer.

Authors:  Shreya Goel; Carolina A Ferreira; Prashant Dogra; Bo Yu; Christopher J Kutyreff; Cerise M Siamof; Jonathan W Engle; Todd E Barnhart; Vittorio Cristini; Zhihui Wang; Weibo Cai
Journal:  Small       Date:  2019-09-29       Impact factor: 13.281

3.  [18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies.

Authors:  Min Chen; Zixin Chen; Jessa B Castillo; Liyang Cui; Kaixiang Zhou; Bin Shen; Jinghang Xie; Frederick T Chin; Jianghong Rao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-13       Impact factor: 9.236

4.  Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer.

Authors:  Vijay S Madamsetty; Anil Sharma; Maria Toma; Stefanie Samaniego; Audrey Gallud; Enfeng Wang; Krishnendu Pal; Debabrata Mukhopadhyay; Bengt Fadeel
Journal:  Nanomedicine       Date:  2019-03-06       Impact factor: 5.307

5.  Physalis Mottle Virus-like Nanoparticles for Targeted Cancer Imaging.

Authors:  He Hu; Hema Masarapu; Yuning Gu; Yifan Zhang; Xin Yu; Nicole F Steinmetz
Journal:  ACS Appl Mater Interfaces       Date:  2019-05-10       Impact factor: 9.229

Review 6.  Integrating nanomedicine into clinical radiotherapy regimens.

Authors:  Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas; Conroy Sun
Journal:  Adv Drug Deliv Rev       Date:  2019-07-04       Impact factor: 15.470

Review 7.  National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.

Authors:  Christopher M Hartshorn; Luisa M Russell; Piotr Grodzinski
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-07-01

Review 8.  A review on core-shell structured unimolecular nanoparticles for biomedical applications.

Authors:  Guojun Chen; Yuyuan Wang; Ruosen Xie; Shaoqin Gong
Journal:  Adv Drug Deliv Rev       Date:  2018-07-20       Impact factor: 15.470

9.  Biodegradable pH-responsive amorphous calcium carbonate nanoparticles as immunoadjuvants for multimodal imaging and enhanced photoimmunotherapy.

Authors:  Meng Wang; Benqing Zhou; Lu Wang; Feifan Zhou; Nataliya Smith; Debra Saunders; Rheal A Towner; Jun Song; Junle Qu; Wei R Chen
Journal:  J Mater Chem B       Date:  2020-09-23       Impact factor: 6.331

Review 10.  Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy.

Authors:  Morgan E Lorkowski; Prabhani U Atukorale; Ketan B Ghaghada; Efstathios Karathanasis
Journal:  Adv Healthc Mater       Date:  2020-11-23       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.